EUVIMEDEUVIMED entdecken
Systematische ÜbersichtOpen Access · CC BY-NC 4.0

Evolving Evidence-Based Value Assessment of One-Time Therapies: Tisagenlecleucel as a Case Study

Theodore Laetsch, Jie Zhang, Hongbo Yang, Yanwen Xie, Dudan Zhang, Louis Garrison

Applied Health Economics and Health Policy · 2024

DOI: 10.1007/s40258-024-00882-4 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift Applied Health Economics and Health Policy, 2024. Verfasst von Theodore Laetsch und 5 weiteren Autor:innen. Beteiligte Einrichtung: Children's Hospital of Philadelphia, Philadelphia, PA, USA. Hauptthemen laut MEDLINE: Cost-Benefit Analysis, Precursor Cell Lymphoblastic Leukemia-Lymphoma. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Novartis Pharmaceuticals Corporation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Economic evaluation of one-time therapies during reimbursement decision-making is challenging due to uncertain long-term outcomes. The availability of 5-year outcome data from the ELIANA trial and real-world evidence of tisagenlecleucel, the first chimeric antigen receptor T-cell (CAR-T) therapy, presents an opportunity to re-evaluate the predictions of prior cost-effectiveness analyses (CEAs). OBJECTIVE: To conduct a systematic literature review (SLR) of prior CEAs of tisagenlecleucel for pediatric/young adult relapsed or refractory acute lymphoblastic leukemia (r/r ALL) and evaluate the impact of recently available 5-year efficacy data from ELIANA and advances in CAR-T manufacturing in an updated CEA model. METHODS: OVID MEDLINE/Embase and health technology assessment (HTA) databases were searched for full-text economic evaluations in English reporting cost-effectiveness results for tisagenlecleucel for r/r ALL. Evaluations with publicly reported incremental cost-effectiveness ratios (ICERs) were included in the SLR. Study screening and data abstraction were conducted following PRISMA guidelines. Data extracted included the country/currency, perspective, clinical trial evidence, model structures, long-term efficacy extrapolation approaches (i.e., overall survival [OS]), time horizon, discount rates, and outcomes (i.e., life years [LY], quality-adjusted LY [QALY], and ICERs). The CEA model reported in Wakase et al. was updated using 5-year OS data from ELIANA and the CAR-T infusion rate informed by real-world practice. RESULTS: Sixteen records corresponding to 15 unique studies were included in the SLR (11 publications and 5 HTA reports); all were conducted from the health care system perspective of the respective countries. Most studies found tisagenlecleucel to be cost effective, but all studies' projected 3- and 5-year OS rates for tisagenlecleucel were lower than the observed 3- and 5-year rates, respectively, derived from 5-year ELIANA data. When applying updated OS projections from the most recent ELIANA data cut and higher infusion rates of 92.5% (per the real-world infusion rate)-96.0% (per the manufacturer success rate) to the CEA of Wakase et al., the associated QALYs for tisagenlecleucel increased from 11.6 to 14.6-15.0, and LYs increased from 13.3 to 17.0-17.5. Accordingly, the ICERs for tisagenlecleucel decreased from ¥2,035,071 to ¥1,787,988-¥1,789,048 versus blinatumomab and from ¥2,644,702 to ¥2,257,837-¥2,275,181 versus clofarabine combination therapy in the updated CEA model. CONCLUSIONS AND RELEVANCE: Projections at launch of the likely cost effectiveness of tisagenlecleucel appear to have underestimated its ultimate economic value given more recent trial and real-world data. To balance uncertainty in initial valuation with the need to provide access to novel oncology therapies, payers can consider flexible reimbursement policies alongside ongoing assessments as new data emerge.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cost-Benefit AnalysisPrecursor Cell Lymphoblastic Leukemia-LymphomaHumansQuality-Adjusted Life YearsReceptors, Antigen, T-CellImmunotherapy, AdoptiveTechnology Assessment, BiomedicalChildYoung Adult

Substanzen

tisagenlecleucelReceptors, Antigen, T-Cell

Autor:innen und Institutionen

  • Children's Hospital of Philadelphia, Philadelphia, PA, USA.
  • Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA.
  • Analysis Group, Inc., Boston, MA, USA. hongbo.yang@analysisgroup.com.
  • Analysis Group, Inc., Beijing, China.
  • School of Pharmacy, University of Washington, Seattle, WA, USA.

Förderung

  • Novartis Pharmaceuticals Corporation

Zitieren

APA

Laetsch, T., Zhang, J., Yang, H., Xie, Y., Zhang, D., & Garrison, L. (2024). Evolving Evidence-Based Value Assessment of One-Time Therapies: Tisagenlecleucel as a Case Study. Applied Health Economics and Health Policy. https://doi.org/10.1007/s40258-024-00882-4

Vancouver

Laetsch T, Zhang J, Yang H, Xie Y, Zhang D, Garrison L. Evolving Evidence-Based Value Assessment of One-Time Therapies: Tisagenlecleucel as a Case Study. Applied Health Economics and Health Policy. 2024. doi:10.1007/s40258-024-00882-4

BibTeX
@article{Laetsch2024,
  author = {Laetsch, Theodore and Zhang, Jie and Yang, Hongbo and Xie, Yanwen and Zhang, Dudan and Garrison, Louis},
  title = {Evolving Evidence-Based Value Assessment of One-Time Therapies: Tisagenlecleucel as a Case Study},
  journal = {Applied Health Economics and Health Policy},
  year = {2024},
  doi = {10.1007/s40258-024-00882-4}
}
Kostenlos starten →